Day: September 15, 2022

SDS of cas: 55981-09-4In 2021, Hooshmand, Seyed Aghil;Zarei Ghobadi, Mohadeseh;Hooshmand, Seyyed Emad;Azimzadeh Jamalkandi, Sadegh;Alavi, Seyed Mehdi;Masoudi-Nejad, Ali published 《A multimodal deep learning-based drug repurposing approach for treatment of COVID-19》. 《Molecular Diversity》published the findings. The article contains the following contents:

Abstract: Recently, various computational methods have been proposed to find new therapeutic applications of the existing drugs. The Multimodal Restricted Boltzmann Machine approach (MM-RBM), which has the capability to connect the information about the multiple modalities, can be applied to the problem of drug repurposing. The present study utilized MM-RBM to combine two types of data, including the chem. structures data of small mols. and differentially expressed genes as well as small mols. perturbations. In the proposed method, two sep. RBMs were applied to find out the features and the specific probability distribution of each datum (modality). Besides, RBM was used to integrate the discovered features, resulting in the identification of the probability distribution of the combined data. The results demonstrated the significance of the clusters acquired by our model. These clusters were used to discover the medicines which were remarkably similar to the proposed medications to treat COVID-19. Moreover, the chem. structures of some small mols. as well as dysregulated genes’ effect led us to suggest using these mols. to treat COVID-19. The results also showed that the proposed method might prove useful in detecting the highly promising remedies for COVID-19 with min. side effects. All the source codes are accessible using https://github.com/LBBSoft/Multimodal-Drug-Repurposing.git Graphic abstract: [graphic not available: see fulltext]. The experimental procedure involved many compounds, such as 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsSDS of cas: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

DeBoer, Mark D.;Platts-Mills, James A.;Elwood, Sarah E.;Scharf, Rebecca J.;McDermid, Joann M.;Wanjuhi, Anne W.;Jatosh, Samwel;Katengu, Siphael;Parpia, Tarina C.;Rogawski McQuade, Elizabeth T.;Gratz, Jean;Svensen, Erling;Swann, Jonathan R.;Donowitz, Jeffrey R.;Mdoe, Paschal;Kivuyo, Sokoine;Houpt, Eric R.;Mduma, Estomih published 《Effect of scheduled antimicrobial and nicotinamide treatment on linear growth in children in rural Tanzania: A factorial randomized, double-blind, placebo-controlled trial》 in 2021. The article was appeared in 《PLoS Medicine》. They have made some progress in their research.COA of Formula: C12H9N3O5S The article mentions the following:

Background: Stunting among children in low-resource settings is associated with enteric pathogen carriage and micronutrient deficiencies. Our goal was to test whether administration of scheduled antimicrobials and daily nicotinamide improved linear growth in a region with a high prevalence of stunting and enteric pathogen carriage. Methods and findings: We performed a randomized, 2 x 2 factorial, double-blind, placebo-controlled trial in the area around Haydom, Tanzania. Mother-child dyads were enrolled by age 14 days and followed with monthly home visits and every 3-mo anthropometry assessments through 18 mo. Those randomized to the antimicrobial arm received 2 medications (vs. corresponding placebos): azithromycin (single dose of 20 mg/kg) at months 6, 9, 12, and 15 and nitazoxanide (3-day course of 100 mg twice daily) at months 12 and 15. Those randomized to nicotinamide arm received daily nicotinamide to the mother (250 mg pills months 0 to 6) and to the child (100 mg sachets months 6 to 18). Primary outcome was length-for-age z-score (LAZ) at 18 mo in the modified intention-to-treat group. Between Sept. 5, 2017 and August 31, 2018, 1,188 children were randomized, of whom 1,084 (n = 277 placebo/placebo, 273 antimicrobial/placebo, 274 placebo/nicotinamide, and 260 antimicrobial/nicotinamide) were included in the modified intention-to-treat anal. The study was suspended for a 3-mo period by the Tanzanian National Institute for Medical Research (NIMR) because of concerns related to the timing of laboratory testing and the total number of serious adverse events (SAEs); this resulted in some participants receiving their final study assessment late. There was a high prevalence of stunting overall (533/1,084, 49.2%). Mean 18-mo LAZ did not differ between groups for either intervention (mean LAZ with 95% confidence interval [CI]: antimicrobial: -2.05 CI -2.13, -1.96, placebo: -2.05 CI -2.14, -1.97; mean difference: 0.01 CI -0.13, 0.11, p = 0.91; nicotinamide: -2.06 CI -2.13, -1.95, placebo: -2.04 CI -2.14, -1.98, mean difference 0.03 CI -0.15, 0.09, p = 0.66). There was no difference in LAZ for either intervention after adjusting for possible confounders (baseline LAZ, age in days at 18-mo measurement, ward, hospital birth, birth month, years of maternal education, socioeconomic status (SES) quartile category, sex, whether the mother was a member of the Datoga tribe, and mother’s height). Adverse events (AEs) and SAEs were overall similar between treatment groups for both the nicotinamide and antimicrobial interventions. Key limitations include the absence of laboratory measures of pathogen carriage and nicotinamide metabolism to provide context for the neg. findings. Conclusions: In this study, we observed that neither scheduled administration of azithromycin and nitazoxanide nor daily provision of nicotinamide was associated with improved growth in this resource-poor setting with a high force of enteric infections. Further research remains critical to identify interventions toward improved early childhood growth in challenging conditions. Trial registration: ClinicalTrials.gov NCT03268902. To complete the study, the researchers used 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsCOA of Formula: C12H9N3O5S

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Walker, Lauren E.;FitzGerald, Richard;Saunders, Geoffrey;Lyon, Rebecca;Fisher, Michael;Martin, Karen;Eberhart, Izabela;Woods, Christie;Ewings, Sean;Hale, Colin;Rajoli, Rajith K. R.;Else, Laura;Dilly-Penchala, Sujan;Amara, Alieu;Lalloo, David G.;Jacobs, Michael;Pertinez, Henry;Hatchard, Parys;Waugh, Robert;Lawrence, Megan;Johnson, Lucy;Fines, Keira;Reynolds, Helen;Rowland, Timothy;Crook, Rebecca;Okenyi, Emmanuel;Byrne, Kelly;Mozgunov, Pavel;Jaki, Thomas;Khoo, Saye;Owen, Andrew;Griffiths, Gareth;Fletcher, Thomas E.;the AGILE platform published 《An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2》 in 2022. The article was appeared in 《Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)》. They have made some progress in their research.Product Details of 55981-09-4 The article mentions the following:

Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease 2019 (COVID-19), but repurposed antivirals have not been successful to date because of redundancy of the target in vivo or suboptimal exposures at studied doses. Nitazoxanide is a US Food and Drug Administration (FDA) approved antiparasitic medicine, that physiol.-based pharmacokinetic (PBPK) modeling has indicated may provide antiviral concentrations across the dosing interval, when repurposed at higher than approved doses. Within the AGILE trial platform (NCT04746183) an open label, adaptive, phase I trial in healthy adult participants was undertaken with high-dose nitazoxanide. Participants received 1500 mg nitazoxanide orally twice-daily with food for 7 days. Primary outcomes were safety, tolerability, optimum dose, and schedule. Intensive pharmacokinetic (PK) sampling was undertaken day 1 and 5 with min. concentration (C_min) sampling on days 3 and 7. Fourteen healthy participants were enrolled between Feb. 18 and May 11, 2021. All 14 doses were completed by 10 of 14 participants. Nitazoxanide was safe and with no significant adverse events. Moderate gastrointestinal disturbance (loose stools or diarrhea) occurred in 8 participants (57.1%), with urine and sclera discoloration in 12 (85.7%) and 9 (64.3%) participants, resp., without clin. significant bilirubin elevation. This was self-limiting and resolved upon drug discontinuation. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median C_min was above the in vitro target concentration on the first dose and maintained throughout. Nitazoxanide administered at 1,500 mg b.i.d. with food was safe with acceptable tolerability a phase Ib/IIa study is now being initiated in patients with COVID-19.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), an anthelmintic agent, exhibits a broad spectrum of activities against a wide variety of helminths, protozoa, and enteric bacteria infecting animals and humans.Product Details of 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Computed Properties of C12H9N3O5S《Synergistic and Antagonistic Drug Combinations against SARS-CoV-2》 was published in 2021. The authors were Bobrowski, Tesia;Chen, Lu;Eastman, Richard T.;Itkin, Zina;Shinn, Paul;Chen, Catherine Z.;Guo, Hui;Zheng, Wei;Michael, Sam;Simeonov, Anton;Hall, Matthew D.;Zakharov, Alexey V.;Muratov, Eugene N., and the article was included in《Molecular Therapy》. The author mentioned the following in the article:

Antiviral drug development for coronavirus disease 2019 (COVID-19) is occurring at an unprecedented pace, yet there are still limited therapeutic options for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2, thus generating better antiviral efficacy. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Sixteen synergistic and eight antagonistic combinations were identified; among 16 synergistic cases, combinations of the US Food and Drug Administration (FDA)-approved drug nitazoxanide with remdesivir, amodiaquine, or umifenovir were most notable, all exhibiting significant synergy against SARS-CoV-2 in a cell model. However, the combination of remdesivir and lysosomotropic drugs, such as hydroxychloroquine, demonstrated strong antagonism. Overall, these results highlight the utility of drug repurposing and preclin. testing of drug combinations for discovering potential therapies to treat COVID-19. The experimental procedure involved many compounds, such as 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Computed Properties of C12H9N3O5S

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Electric Literature of C12H9N3O5SIn 2022, Farid, Alyaa;Yousry, Mona;Safwat, Gehan published 《Garlic (Allium sativum Linnaeus) improved inflammation and reduced cryptosporidiosis burden in immunocompromised mice》. 《Journal of Ethnopharmacology》published the findings. The article contains the following contents:

For thousands of years, garlic (Allium sativum Linnaeus) has been consumed in food and health by numerous civilizations. Cryptosporidium (C.) parvum is an apicomplexan parasite that causes a gastrointestinal disease, with the most common symptoms being watery diarrhea. Although several substances have been tried for its anti-cryptosporidial action, there is no effective treatment for Cryptosporidium disease, especially in immunocompromised individuals. The present study aimed firstly to characterize the bio-active compounds in Allium sativum L. and secondly to evaluate its efficacy as a therapy for cryptosporidiosis especially in immunocompromised mice. This was accomplished by evaluating the parasitol. and histopathol. parameters in the exptl. infected immunocompetent and immunocompromised mice. Also, the cytokine profile during the exptl. time was recorded through the measuring of T helper (h)1, Th2 and Th17 cells cytokines. Immunosuppressed mice were given 0.25μg/g per day of dexamethasone orally, before infection with Cryptosporidium parvum oocysts, for fourteen consecutive days. Starting 10 days post infection (PI), nitazoxanide (100 mg/kg per day) or Allium sativum (50 mg/kg per day) was given orally for fourteen consecutive days. Our results showed that oocyst shedding, on the 32nd day PI, in immunocompromised infected group treated with Allium sativum (354.11, 99.35% PR) showed a significant decrease when compared to its corresponding group treated with nitazoxanide (4369.14, 92.05% PR). On the 32nd day PI, all cytokines levels have been decreased to levels that were similar to those of their uninfected corresponding control groups; also, the histopathol. changes and the loss in animals body weight had been improved. Treatment with nitazoxanide did not result in infection clearance or a reduction in the increased cytokines levels.Allium sativum L. displayed high efficacy as a potential therapeutic agent against Cryptosporidium, which supports its traditional usage in parasite diseases. And 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) was used in the research process.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Electric Literature of C12H9N3O5S

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

SDS of cas: 55981-09-4In 2021, Omolabi, Kehinde F.;Iwuchukwu, Emmanuel A.;Agoni, Clement;Olotu, Fisayo A.;Soliman, Mahmoud E. S. published 《A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase》. 《Journal of Molecular Modeling》published the findings. The article contains the following contents:

Compound P131 has been established to inhibit Cryptosporidium parvum′s inosine monophosphate dehydrogenase (CpIMPDH). Its inhibitory activity supersedes that of paromomycin, which is extensively used in treating cryptosporidiosis. Through the per-residue energy decomposition approach, crucial moieties of P131 were identified and subsequently adopted to create a pharmacophore model for virtual screening in the ZINC database. This search generated eight ADMET-compliant hits that were examined thoroughly to fit into the active site of CpIMPDH via mol. docking. Three compounds ZINC46542062, ZINC58646829, and ZINC89780094, with favorable docking scores of – 8.3 kcal/mol, – 8.2 kcal/mol, and – 7.5 kcal/mol, were selected. The potential inhibitory mechanism of these compounds was probed using mol. dynamics simulation and Mol. Mechanics Generalized Poisson Boltzmann Surface Area (MM/PBSA) analyses. Results revealed that one of the hits (ZINC46542062) exhibited a lower binding free energy of – 39.52 kcal/mol than P131, which had – 34.6 kcal/mol. Conformational perturbation induced by the binding of the identified hits to CpIMPDH was similar to P131, suggesting a similarity in inhibitory mechanisms. Also, in silico investigation of the properties of the hit compounds implied superior physicochem. properties with regards to their synthetic accessibility, lipophilicity, and number of hydrogen bond donors and acceptors in comparison with P131. ZINC46542062 was identified as a promising hit compound with the highest binding affinity to the target protein and favorable physicochem. and pharmacokinetic properties relative to P131. The identified compounds can serve as a basis for conducting further exptl. investigations toward the development of anticryptosporidials, which can overcome the challenges of existing therapeutic options. Graphical abstractP131 and the identified compounds docked in the NAD+ binding site of Cryptosporidium parvum IMPDH . And 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) was used in the research process.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been approved as an orphan drug for the treatment of diarrhea in children (age, 1–11 years) and is associated with giardiasis, but it also is approved for diarrhea caused by crytosporidiosis in patients with AIDS.SDS of cas: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Olagunju, Adeniyi;Fowotade, Adeola;Olagunoye, Ajibola;Ojo, Temitope Olumuyiwa;Adefuye, Bolanle Olufunlola;Fagbamigbe, Adeniyi Francis;Adebiyi, Akindele Olupelumi;Olagunju, Omobolanle Ibitayo;Ladipo, Olabode Taiwo;Akinloye, Abdulafeez;Adeagbo, Babatunde Ayodeji;Onayade, Adedeji;Bolaji, Oluseye Oladotun;Happi, Christian;Rannard, Steve;Owen, Andrew published 《Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial》. The research results were published in《Trials》 in 2021.Recommanded Product: 55981-09-4 The article conveys some information:

To investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in shortening the time to clin. improvement and achievement of SARS-CoV-2 polymerase chain reaction (PCR) negativity in patients diagnosed with moderate to severe COVID-19. This is a pilot phase 2, multicentre 2-arm (1:1 ratio) open-label randomised controlled trial. Patients with confirmed COVID-19 diagnosis (defined as SARS-CoV-2 PCR pos. nasopharyngeal swab) will be recruited from four participating isolation and treatment centers in Nigeria: two secondary care facilities (Infectious Diseases Hospital, Olodo, Ibadan, Oyo State and Specialist State Hospital, Asubiaro, Osogbo, Osun State) and two tertiary care facilities (Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State and Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State). These facilities have a combined capacity of 146-bed COVID-19 isolation and treatment ward. Confirmation of SARS-CoV-2 infection by PCR test within two days before randomisation and initiation of treatment, age bracket of 18 and 75 years, symptomatic, able to understand study information and willingness to participate. Exclusion criteria include the inability to take orally administered medication or food, known hypersensitivity to any of the study drugs, pregnant or lactating, current or recent (within 24 h of enrolment) treatment with agents with actual or likely antiviral activity against SARS-CoV-2, concurrent use of agents with known or suspected interaction with study drugs, and requiring mech. ventilation at screening. Participants in the intervention group will receive 1000 mg of nitazoxanide twice daily orally and 300/100 mg of atazanvir/ritonavir once daily orally in addition to standard of care while participants in the control group will receive only standard of care. Standard of care will be determined by the physician at the treatment center in line with the current guidelines for clin. management of COVID-19 in Nigeria. Main outcome measures are: (1) Time to clin. improvement (defined as time from randomisation to either an improvement of two points on a 10-category ordinal scale (developed by the WHO Working Group on the Clin. Characterization and Management of COVID-19 infection) or discharge from the hospital, whichever came first); (2) Proportion of participants with SARS-CoV-2 polymerase chain reaction (PCR) neg. result at days 2, 4, 6, 7, 14 and 28; (3) Temporal patterns of SARS-CoV-2 viral load on days 2, 4, 6, 7, 14 and 28 quantified by RT-PCR from saliva of patients receiving standard of care alone vs. standard of care plus study drugs. Randomisation: Allocation of participants to study arm is randomised within each site with a ratio 1:1 based on randomisation sequences generated centrally at Obafemi Awolowo University. The model was implemented in REDCap and includes stratification by age, gender, viral load at diagnosis and presence of relevant comorbidities. None, this is an open-label trial. 98 Patients (49 per arm). Regulatory approval was issued by the National Agency for Food and Drug Administration and Control on 06 Oct. 2020 (protocol version number is 2.1 dated 06 August 2020). Recruitment started on 9 Oct. 2020 and is anticipated to end before Apr. 2021. And 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) was used in the research process.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Recommanded Product: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Formula: C12H9N3O5SIn 2022, AbdelGhaffar, Muhammad M.;Omran, Dalia;Elgebaly, Ahmed;Bahbah, Eshak I.;Afify, Shimaa;AlSoda, Mohamed;El-Shiekh, Mohamed;ElSayed, Enass S.;Shaaban, Soha S.;AbdelHafez, Samah;Elkelany, Khaled;Eltayar, Ayman A.;Ali, Omnia S.;Kamal, Lamiaa;Heiba, Ahmed M.;El Askary, Ahmad;Shousha, Hend Ibrahim published 《Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study》. 《PLoS One》published the findings. The article contains the following contents:

A aimed to assess the epidemiol., clin., and laboratory characteristics associated with mortality among hospitalized Egyptian patients with COVID-19. A multicenter, retrospective study was conducted on all polymerase chain reaction (PCR)-confirmed COVID-19 cases admitted through the period from Apr. to July 2020. A generalized linear model was reconstructed with covariates based on predictor’s statistical significance and clin. relevance. The odds ratio (OR) was calculated by using stepwise logistic regression modeling. A total of 3712 hospitalized patients were included; of them, 900 deaths were recorded (24.2%). Compared to survived patients, non-survived patients were more likely to be older than 60 years (65.7%), males (53.6%) diabetic (37.6%), hypertensive (37.2%), and had chronic renal insufficiency (9%). Non-survived patients were less likely to receive azithromycin (p <0.001), anticoagulants (p <0.001), and steroids (p <0.001). In this found that age ≥ 60 years old (OR = 2.82, 95% CI 2.05-3.86; p <0.0001), diabetes mellitus (OR = 1.58, 95% CI 1.14-2.19; p = 0.006), hypertension (OR = 1.69, 95% CI 1.22-2.36; p = 0.002), chronic renal insufficiency (OR = 3.15, 95% CI 1.84-5.38; p <0.0001), tachycardia (OR = 1.65, 95% CI 1.22-2.23; p <0.001), hypoxemia (OR = 5.69, 95% CI 4.05-7.98; p <0.0001), GCS <13 (OR 515.2, 95% CI 148.5-1786.9; p <0.0001), the use of therapeutic dose of anticoagulation (OR = 0.4, 95% CI 0.22-0.74, p = 0.003) and azithromycin (OR = 0.16, 95% CI 0.09-0.26; p <0.0001) were independent neg. predictors of mortality. In conclusion, age >60 years, comorbidities, tachycardia, hypoxemia, and altered consciousness level are independent predictors of mortality among Egyptian hospitalized patients with COVID-19. On the other hand, the use of anticoagulants and azithromycin is associated with reduced mortality.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been approved as an orphan drug for the treatment of diarrhea in children (age, 1–11 years) and is associated with giardiasis, but it also is approved for diarrhea caused by crytosporidiosis in patients with AIDS.Formula: C12H9N3O5S

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Shrivastava, Garima;Shrivastava, Manjul published 《Microwave assisted synthesis and characterization of Schiff base of 2-amino-6-nitrobenzothiazole》 in 2018. The article was appeared in 《International Research Journal of Pharmacy》. They have made some progress in their research.Category: thiazole The article mentions the following:

Synthesis of Schiff base I via microwave-induced condensation reaction of 2-amino-6-nitro benzothiazole and 3,5-diiodosalicylaldehyde was reported. The method used in the study was eco friendly and provided many benefits such as to straightforward work-up procedure, short reaction times, non-hazardous and good yield of product.6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) were involved in the experimental procedure.

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0) has been used:
as model analyte for voltammetric determination of electrochemically reducible organic substances;
in the synthesis of 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2-(cyclohexanecarbonylamino)benzothiazol-6-yl]amide derivatives;
in the preparation of push-pull nonlinear optical chromophores containing thiazole and benzothiazole acceptors;
as a base in dye production by diazotation reaction.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Mikherdov, A. S.;Baikov, S. V.;Proskurina, I. K.;Shetnev, A. A.;Kotov, A. D. published 《Synthesis and Properties of C,N-Chelated Carbene Complexes of Palladium(II) with 2-Aminobenzo[d]thiazole Fragment》. The research results were published in《Russian Journal of General Chemistry》 in 2019.Name: 6-Nitrobenzo[d]thiazol-2-amine The article conveys some information:

The reaction of bis(cyclohexylisocyanide) complex of Pd(II) with substituted benzo[d]thiazole-2-amines in the presence of triethanolamine as the base has lead to the formation of deprotonated C,N-chelated carbene complexes with a structure similar to that described previously for the products of the reaction with unsubstituted benzo[d]thiazole-2-amine. The complexes have been isolated and characterized using high-resolution mass spectrometry, IR and NMR spectroscopy (¹H, ¹³C{¹H}, ¹H-¹H COSY, ¹H-¹H NOESY, ¹H-¹³C HSQC, ¹H-¹³C HMBC). The resulting complexes have exhibited moderate antibacterial activity against sensitive strains of gram-neg. bacteria E. coli (C600) and P. fluorescens (P218), gram-pos. bacteria S. aureus (ATCC-25923) and B. subtillis (B-3142D) as well as fungi C. albicans (401/NCTC-885-653).6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) were involved in the experimental procedure.

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Name: 6-Nitrobenzo[d]thiazol-2-amine) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica